Condition category
Cancer
Date applied
01/07/2001
Date assigned
01/07/2001
Last edited
04/01/2012
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Not provided at time of registration

Trial website

Contact information

Type

Scientific

Primary contact

Dr - -

ORCID ID

Contact details

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

GA3004

Study information

Scientific title

Acronym

Study hypothesis

Not provided at time of registration

Ethics approval

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Not specified

Trial type

Not Specified

Patient information sheet

Condition

Oesophagus, stomach cancer

Intervention

Patients are randomised to one of four treatment arms:
1. Arm A: Cimetidine 400 mg twice daily until death.
2. Arm B: Cimetidine 400 mg once daily until death.
3. Arm C: Placebo tablet twice daily until death.
4. Arm D: Placebo tablet once daily until death.

Intervention type

Drug

Phase

Not Specified

Drug names

cimeditine

Primary outcome measures

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall trial start date

01/01/1994

Overall trial end date

31/03/1995

Reason abandoned

Eligibility

Participant inclusion criteria

1. Biopsy proven adenocarcinoma of the stomach, any stage of disease, whether removed curatively or palliatively, or unresectable
2. Able to swallow tablets
3. No other concurrent cancer at other primary sites
4. No other serious illness, limiting prognosis severely

Participant type

Patient

Age group

Not Specified

Gender

Not Specified

Target number of participants

Not provided at time of registration

Participant exclusion criteria

Not provided at time of registration

Recruitment start date

01/01/1994

Recruitment end date

31/03/1995

Locations

Countries of recruitment

United Kingdom

Trial participating centre

UKCCCR Register Co-ordinator
London
NW1 2DA
United Kingdom

Sponsor information

Organisation

Cancer Research UK (CRUK) (UK)

Sponsor details

PO Box 123
Lincoln's Inn Fields
London
WC2A 3PX
United Kingdom
+44 (0)207 317 5186
kate.law@cancer.org.uk

Sponsor type

Charity

Website

http://www.cancer.org.uk

Funders

Funder type

Industry

Funder name

Cancer Research UK

Alternative name(s)

CRUK

Funding Body Type

private sector organisation

Funding Body Subtype

other non-profit

Location

United Kingdom

Funder name

Smithkline Beecham Pharmaceuticals

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

1. 1999 results in http://www.ncbi.nlm.nih.gov/pubmed/10604733

Publication citations

  1. Results

    Langman MJ, Dunn JA, Whiting JL, Burton A, Hallissey MT, Fielding JW, Kerr DJ, Prospective, double-blind, placebo-controlled randomized trial of cimetidine in gastric cancer. British Stomach Cancer Group., Br. J. Cancer, 1999, 81, 8, 1356-1362, doi: 10.1038/sj.bjc.6690457.

Additional files

Editorial Notes